Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

BAY 85-3934 is a pan-inhibitor of hypoxia-inducible factor prolyl hydroxylases (HIF-PH; IC50s = 0.48, 0.28, and 0.45 µM for HIF-PH1, HIF-PH2, and HIF-PH3, respectively).1 It stabilizes HIF-1α and HIF-2α levels in HeLa cells in a concentration- and time-dependent manner. BAY 85-3934 (50 µM) induces cell-cycle arrest at the G2/S phase in MDA-MB-231 breast cancer cells.2 It decreases lactate dehydrogenase (LDH) release from PC12 cells in an in vitro model of ischemia induced by oxygen-glucose deprivation when used at a concentration of 100 µM.3 BAY 85-3934 (5 mg/kg) increases plasma erythropoietin and hemoglobin levels, as well as packed cell volume, in a rat model of gentamicin-induced kidney failure.1
WARNING This product is not for human or veterinary use.
1. Mimicking hypoxia to treat anemia: HIF-
2. HIF-
3. Hypoxia-
Bidirectional modulation of HIF-